Literature DB >> 23890523

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.

Naval Daver1, Aditi Shastri, Tapan Kadia, Alfonso Quintas-Cardama, Elias Jabbour, Marina Konopleva, Susan O'Brien, Sherry Pierce, Lingsha Zhou, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek.   

Abstract

We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5mg/day continuously. Three patients (10%) experienced clinical improvement in hemoglobin per International-Working-Group criteria (median time to response 1.6 months; median response duration 6.7 months). Ten patients were RBC-transfusion-dependent per Delphi criteria; 2 (20%) achieved RBC-transfusion-independence (time to response 0.9 months in both; response duration of 8.3 and 15 months). One grade 3/4 toxicity (neutropenia) occurred. Pomalidomide at low dose is well tolerated but has modest clinical activity in myelofibrosis.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anemia; Myelofibrosis; Pomalidomide

Mesh：

Substances：

Year:  2013        PMID： 23890523      PMCID： PMC4232180          DOI： 10.1016/j.leukres.2013.07.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  37 in total

1.  Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level.

Authors:  Jocelin Huang; Ayalew Tefferi
Journal:  Eur J Haematol       Date:  2009-04-10       Impact factor: 2.997

2.  Phase1/-2 study of Pomalidomide in myelofibrosis.

Authors:  Ruben A Mesa; Animesh D Pardanani; Kebede Hussein; Wenting Wu; Susan Schwager; Mark R Litzow; William J Hogan; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2010-02       Impact factor: 10.047

3.  A phase-2 trial of low-dose pomalidomide in myelofibrosis.

Authors:  K H Begna; R A Mesa; A Pardanani; W J Hogan; M R Litzow; R F McClure; A Tefferi
Journal:  Leukemia       Date:  2010-11-05       Impact factor: 11.528

4.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

5.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Authors:  Naseema Gangat; Domenica Caramazza; Rakhee Vaidya; Geeta George; Kebede Begna; Susan Schwager; Daniel Van Dyke; Curtis Hanson; Wenting Wu; Animesh Pardanani; Francisco Cervantes; Francesco Passamonti; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

6.  What are RBC-transfusion-dependence and -independence?

Authors:  R P Gale; G Barosi; T Barbui; F Cervantes; K Dohner; B Dupriez; V Gupta; C Harrison; R Hoffman; J-J Kiladjian; R Mesa; M F Mc Mullin; F Passamonti; V Ribrag; G Roboz; G Saglio; A Vannucchi; S Verstovsek
Journal:  Leuk Res       Date:  2010-08-07       Impact factor: 3.156

7.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

8.  Pomalidomide is active in the treatment of anemia associated with myelofibrosis.

Authors:  Ayalew Tefferi; Srdan Verstovsek; Giovanni Barosi; Francesco Passamonti; Gail J Roboz; Heinz Gisslinger; Ronald L Paquette; Francisco Cervantes; Candido E Rivera; H Joachim Deeg; Juergen Thiele; Hans M Kvasnicka; James W Vardiman; Yanming Zhang; B Nebiyou Bekele; Ruben A Mesa; Robert P Gale; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

9.  In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm.

Authors:  Jonathan R Lambert; Tamara Everington; David C Linch; Rosemary E Gale
Journal:  Blood       Date:  2009-06-18       Impact factor: 22.113

10.  Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.

Authors:  Alfonso Quintás-Cardama; Hagop M Kantarjian; Taghi Manshouri; Deborah Thomas; Jorge Cortes; Farhad Ravandi; Guillermo Garcia-Manero; Alessandra Ferrajoli; Carlos Bueso-Ramos; Srdan Verstovsek
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
View more
  13 in total

Review 1.  Management of Myelofibrosis-Related Cytopenias.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 2.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

3.  Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.

Authors:  Naval Daver; Aditi Shastri; Tapan Kadia; Kate Newberry; Naveen Pemmaraju; Elias Jabbour; Linghsa Zhou; Sherry Pierce; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2014-07-06       Impact factor: 3.156

4.  Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

Authors:  R F Schlenk; F Stegelmann; A Reiter; E Jost; N Gattermann; H Hebart; C Waller; A Hochhaus; U Platzbecker; P Schafhausen; I W Blau; W Verbeek; F H Heidel; M Werner; H Kreipe; V Teleanu; A Benner; H Döhner; M Grießhammer; K Döhner
Journal:  Leukemia       Date:  2016-10-24       Impact factor: 11.528

Review 5.  Myelofibrosis: an update on drug therapy in 2016.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2016-11-07       Impact factor: 3.889

6.  Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.

Authors:  Naval Daver; Jorge Cortes; Kate Newberry; Elias Jabbour; Lingsha Zhou; Xuemei Wang; Sherry Pierce; Tapan Kadia; Koji Sasaki; Gautam Borthakur; Farhad Ravandi; Naveen Pemmaraju; Hagop Kantarjian; Srdan Verstovsek
Journal:  Haematologica       Date:  2015-06-18       Impact factor: 9.941

7.  Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

Authors:  Tariq I Mughal; Kris Vaddi; Nicholas J Sarlis; Srdan Verstovsek
Journal:  Int J Gen Med       Date:  2014-01-29

Review 8.  Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.

Authors:  A Yacoub; O Odenike; S Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 9.  Profile of pomalidomide and its potential in the treatment of myelofibrosis.

Authors:  Krisstina L Gowin; Ruben A Mesa
Journal:  Ther Clin Risk Manag       Date:  2015-04-02       Impact factor: 2.423

10.  Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy.

Authors:  Harpreet Kochhar; Chantal S Leger; Heather A Leitch
Journal:  Case Rep Hematol       Date:  2015-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.